ClinicalTrials.gg
CompletedNCT01976104Updated Feb 27, 2018Results posted

Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

A Phase 3 interventional study of avatrombopag (lower baseline platelet count) and placebo (lower baseline platelet count) in Thrombocytopenia Associated With Liver Disease, sponsored by Eisai Inc.. Completed at 122 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-27.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing avatrombopag in Thrombocytopenia — 6 open to participants now, 6 under way, 2 of them phase 3. avatrombopag · Thrombocytopenia.

Enrollment
4th of 23
204 · median 50
Started
2013
with 1 other
Phase 3
5 of 23
1 open now
Registered
3rd of 23
by date
Lead sponsor
5 of 23
Eisai Inc.

Among the 23 studies testing avatrombopag in Thrombocytopenia, this one is the 4th largest by enrollment, is one of 2 that started in 2013, is one of 5 in phase 3, and was the 3rd registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

6 of the 23 studies testing avatrombopag in Thrombocytopenia are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About avatrombopag

avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing avatrombopag in Thrombocytopenia, or all of them as a file.
02

Study summary

This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel group study using avatrombopag to treat adults with thrombocytopenia associated with liver disease. The study will evaluate avatrombopag in the treatment of thrombocytopenia associated with liver disease prior to an elective procedure to reduce the need for platelet transfusions or any rescue procedure for bleeding due to procedural and post-procedural bleeding complications. Participants will be enrolled into 2 cohorts according to mean baseline platelet count and, within each baseline platelet count cohort will be further stratified by risk of bleeding associated with the elective procedure (low, moderate, or high) and hepatocellular carcinoma (HCC) status (Yes or No).

Read the detailed description

This study will consist of 3 phases: Prerandomization, Randomization, and a Follow-up Phase. The Prerandomization Phase includes one Screening Visit that will take place from Day -14 through Day -1; the Randomization Phase includes the Baseline Period, Treatment Period, and Procedure Day Period (5 to 8 days after last dose of study drug [Study Day 10 to 13]). The Follow-up Phase comprises 2 visits: 7 days post Procedure Day and 30 days after receiving the last dose of study drug. Permitted procedures include: Paracentesis; Thoracentesis; Gastrointestinal endoscopy with or without plans for biopsy, colonoscopy, polypectomy, or variceal banding; Liver biopsy; Bronchoscopy with or without plans for biopsy; Ethanol ablation therapy or chemoembolization for HCC; Vascular catheterization (including right side procedures in participants with pulmonary hypertension); Transjugular intrahepatic portosystemic shunt; Dental procedures; Renal biopsy; Biliary interventions; Nephrostomy tube placement; Radiofrequency ablation; and Laparoscopic interventions.

03

Conditions studied

  • Thrombocytopenia Associated With Liver Disease

Browse trials for

Keywords

  • Thrombocytopenia
  • Chronic Liver Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants greater than or equal to 18 years of age at Screening with chronic liver disease
  2. Participants who have a mean baseline count of less than 50 x 10\^9/L. Platelet counts must be measured on 2 separate occasions, during the Screening Period and at Baseline, and must be performed at least one day apart with neither platelet count greater than 60 x 10\^9/L. The mean of these 2 platelet counts (mean baseline platelet count) will be used for entry criteria and for assignment to the low or high baseline platelet count cohort.
  3. Participants scheduled to undergo a permitted elective procedure who, in the opinion of the investigator, will require a platelet transfusion to address a risk of bleeding associated with the procedure unless there is a increase in platelet count from baseline
  4. Model For End-stage Liver Disease (MELD) score less than or equal to 24 at Screening
  5. If taking inhibitors of P glycoprotein (P-gp), except for verapamil, dose must be stable for 7 days prior to Screening
  6. Provide written
  7. Willing and able to comply with all aspects of the protocol

Exclusion criteria

Exclusion Criteria

  1. Any history of arterial or venous thrombosis, including partial or complete thrombosis
  2. Evidence of thrombosis (partial or complete) in the main portal vein, portal vein branches, or any part of the splenic mesenteric system at Screening
  3. Portal vein blood flow velocity rate \<10 centimeters/second at Screening
  4. Hepatic encephalopathy that cannot be effectively treated
  5. Participants with HCC with Barcelona Clinic Liver Cancer (BCLC) staging classification C or D
  6. transfusion or receipt of blood products containing platelets within 7 days of Screening. However packed red blood cells are permitted.
  7. Heparin, warfarin, nonsteroidal anti-inflammatory drugs (NSAID), aspirin, verapamil, and antiplatelet therapy with ticlopidine or glycoprotein IIb/IIIa antagonists (eg, tirofiban) within 7 days of Screening
  8. Use of erythropoietin stimulating agents within 7 days of Screening
  9. Interferon (IFN) use within 14 days of Screening
  10. Estrogen-containing hormonal or hormone replacement therapy use within 30 days of Screening
  11. Active infection requiring systemic antibiotic therapy within 7 days of Screening. However, prophylactic use of antibiotics is permitted.
  12. Alcohol abuse, alcohol dependence syndrome, drug abuse, or drug dependence within 6 months of the study start (unless participating in a controlled rehabilitation program) or acute alcoholic hepatitis (chronic alcoholic hepatitis is allowed) within 6 months of the study start
  13. Elective procedure performed prior to Visit 4 (Procedure Day)
  14. Known to be positive
  15. Any acute or active bleeding (eg, gastrointestinal, central nervous system)
  16. Known history of any primary hematologic disorder (eg, immune thrombocytopenic purpura, myelodysplastic syndrome)
  17. Known medical history of genetic prothrombotic syndromes (eg, Factor V Leiden; prothrombin G20210A; ATIII deficiency, etc.)
  18. Participants with a history of significant cardiovascular disease (eg, congestive heart failure Grade III/IV, arrhythmia known to increase the risk of thromboembolic events [eg, atrial fibrillation], coronary artery stent placement, angioplasty, and coronary artery bypass grafting)
  19. Females of who have had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a progesterone-only contraceptive implant/injection, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. If currently abstinent, the participant must agree to use a double-barrier method as described above if she becomes sexually active during the study period or for 30 days after study drug discontinuation. All females will be considered to be of childbearing potential unless they are (at least 12 months consecutive amenorrhea in the appropriate age group and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) at least 1 month before dosing.
  20. Females who are lactating or pregnant at Screening or Baseline (as documented by a positive serum beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity 25 IU/L or equivalent units of B-hCG). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
  21. Post liver transplant subjects
  22. Any participant who has previously received avatrombopag
  23. to avatrombopag maleate or any of its
  24. levels ≤ 8.0 or ≥ 18.0 g/dL for men and > 15 for women at Screening, with hematocrit ≥ 54% for men and ≥ 45% for women
  25. Current including solid tumors and hematologic malignancies (except HCC)
  26. Any history of concomitant medical condition that, in the opinion of the investigator(s), would compromise the participant's ability to safely complete the study
  27. Currently enrolled in another clinical trial with any drug or device within 30 days of Screening
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
204 participants (actual)

Study arms

  • Experimental
    Group A (avatrombopag, lower baseline platelet count)

    60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5

    Drug: avatrombopag (lower baseline platelet count)

  • Placebo comparator
    Group B (placebo, lower baseline platelet count)

    placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5

    Drug: placebo (lower baseline platelet count)

  • Experimental
    Group C (avatrombopag, higher baseline platelet count)

    40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5

    Drug: avatrombopag (higher baseline platelet count)

  • Placebo comparator
    Group D (placebo, higher baseline platelet count)

    placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5

    Drug: placebo (higher baseline platelet count)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Did Not Require a Platelet Transfusion After Randomization and up to 7 Days Following a Scheduled Procedure

    Responders were defined as participants who did not require a platelet transfusion or any rescue procedure for bleeding after randomization and up to 7 days following a scheduled procedure. Participants with missing information due to early withdrawal or other reasons were conservatively considered as having received a transfusion in the analysis, (i.e. a Non-responder).

    Time frame: Randomization (Visit 2), up to 7 Days following a scheduled procedure

Secondary outcomes

  1. Percentage of Participants Who Achieved a Platelet Count Greater Than or Equal to 50 x 10^9/L on Scheduled Procedure Day

    Responders were defined as participants who achieved a platelet count greater than or equal to 50 x 10\^9/L on the procedure day. Participants missing a platelet count on the procedure day were conservatively considered as not achieving a platelet count of 50x10\^9/L in the analysis, (i.e. Non-responders).

    Time frame: Day 10 to Day 13 (Visit 4)

  2. Change From Baseline in Platelet Counts on Scheduled Procedure Day

    Last observation carried forward was used for participants with a missing platelet count on the scheduled procedure day. Platelet count was measured preprocedure and before any platelet transfusion.

    Time frame: Baseline (Visit 2) to Procedure Day 10 to Day 13 (Visit 4)

Other outcomes

  1. Percentage of Participants With a World Health Organization (WHO) Bleeding Score Greater Than or Equal to 2 After Randomization and up to 7 Days After an Scheduled Procedure

    The severity of bleeding events was assessed by the investigator (or appropriately delegated study site personnel) using the WHO bleeding scale. The WHO bleeding scale is a clinical investigator-assessed five-point scale with Grade 0 = No bleeding, Grade 1 = Petechial bleeding, Grade 2 = Mild blood loss (clinically significant), Grade 3 = Gross blood loss requires transfusion (severe), and Grade 4 = Debilitating blood loss, retinal or cerebral associated with fatality. Participants with missing information are considered as having a WHO bleeding score greater than or equal to 2 in the analysis.

    Time frame: Baseline (Visit 2) up to 7 days post scheduled procedure

  2. Number of Participants Experiencing an Adverse Event

    Safety assessments consisted of monitoring and recording all adverse events (AEs) and serious adverse events, including platelet transfusion-related complications; routine laboratory evaluation for hematology, serum chemistry, and urine values; periodic measurement of vital signs and electrocardiograms (ECGs); the performance of physical examinations; and Doppler sonography. AE severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death related to the AE. All AEs graded as 4 or 5 were considered to be serious. Treatment-emergent adverse events (TEAEs) were defined as an AE that started on or after the date of first dose of study drug, up to 30 days after the last dose of study drug. Treatment-related AEs were considered by the investigator to be possibly or probably related to study drug.

    Time frame: From date of first dose of study drug up to 30 days after the last dose of study drug, up to approximately 3 years and 2 months

07

Results

Posted Feb 27, 2018

Participant flow

Participant flow — Overall Study
Milestone60 mg Placebo (Lower Baseline Platelet Count)60 mg Avatrombopag (Lower Baseline Platelet Count)40 mg Placebo (Higher Baseline Platelet Count)40 mg Avatrombopag (Higher Baseline Platelet Count)
Started43703358
Completed37683155
Not completed6223
Withdrew: Adverse event0010
Withdrew: Lost to follow-up3011
Withdrew: Subject choice0101
Withdrew: Withdrawal by subject3001
Withdrew: Other0100

Outcome measures

PrimaryPercentage of Participants Who Did Not Require a Platelet Transfusion After Randomization and up to 7 Days Following a Scheduled Procedure

Responders were defined as participants who did not require a platelet transfusion or any rescue procedure for bleeding after randomization and up to 7 days following a scheduled procedure. Participants with missing information due to early withdrawal or other reasons were conservatively considered as having received a transfusion in the analysis, (i.e. a Non-responder).

Time frame:
Randomization (Visit 2), up to 7 Days following a scheduled procedure
Reported as:
Number · Percentage of participants
Percentage of Participants Who Did Not Require a Platelet Transfusion After Randomization and up to 7 Days Following a Scheduled Procedure
Percentage of participants60 mg Placebo (Lower Baseline Platelet Count)60 mg Avatrombopag (Lower Baseline Platelet Count)40 mg Placebo (Higher Baseline Platelet Count)40 mg Avatrombopag (Higher Baseline Platelet Count)
Percentage of Participants Who Did Not Require a Platelet Transfusion After Randomization and up to 7 Days Following a Scheduled Procedure34.9 (20.6 to 49.1)68.6 (57.7 to 79.4)33.3 (17.2 to 49.4)87.9 (79.5 to 96.3)
Statistical analysis
  • 60 mg Placebo (Lower Baseline Platelet Count) vs 60 mg Avatrombopag (Lower Baseline Platelet Count) · Cochran-Mantel-Haenszel · p = =0.0006 · Difference of proportion versus placebo: 33.7 · 95% CI 15.8 to 51.6Difference of proportion vs placebo = proportion of Responders for avatrombopag - proportion of Responders for placebo; 95% CI is calculated based on normal approximation.
  • 40 mg Placebo (Higher Baseline Platelet Count) vs 40 mg Avatrombopag (Higher Baseline Platelet Count) · Cochran-Mantel-Haenszel · p = <0.0001 · Difference of proportion versus placebo: 54.6 · 95% CI 36.5 to 72.7Difference of proportion vs placebo = proportion of Responders for avatrombopag - proportion of Responders for placebo; 95% CI is calculated based on normal approximation.
SecondaryPercentage of Participants Who Achieved a Platelet Count Greater Than or Equal to 50 x 10^9/L on Scheduled Procedure Day

Responders were defined as participants who achieved a platelet count greater than or equal to 50 x 10\^9/L on the procedure day. Participants missing a platelet count on the procedure day were conservatively considered as not achieving a platelet count of 50x10\^9/L in the analysis, (i.e. Non-responders).

Time frame:
Day 10 to Day 13 (Visit 4)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a Platelet Count Greater Than or Equal to 50 x 10^9/L on Scheduled Procedure Day
Percentage of participants60 mg Placebo (Lower Baseline Platelet Count)60 mg Avatrombopag (Lower Baseline Platelet Count)40 mg Placebo (Higher Baseline Platelet Count)40 mg Avatrombopag (Higher Baseline Platelet Count)
Percentage of Participants Who Achieved a Platelet Count Greater Than or Equal to 50 x 10^9/L on Scheduled Procedure Day7.0 (0.0 to 14.6)67.1 (56.1 to 78.1)39.4 (22.7 to 56.1)93.1 (86.6 to 99.6)
Statistical analysis
  • 60 mg Placebo (Lower Baseline Platelet Count) vs 60 mg Avatrombopag (Lower Baseline Platelet Count) · Cochran-Mantel-Haenszel · p = <0.0001 · Difference of proportion versus placebo: 60.2 · 95% CI 46.8 to 73.5Difference of proportion vs placebo = proportion of responders for avatrombopag - proportion of responders for placebo; 95% CI is calculated based on normal approximation.
  • 40 mg Placebo (Higher Baseline Platelet Count) vs 40 mg Avatrombopag (Higher Baseline Platelet Count) · Cochran-Mantel-Haenszel · p = <0.0001 · Difference of proportion versus placebo: 53.7 · 95% CI 35.8 to 71.6Difference of proportion vs placebo = proportion of responders for avatrombopag - proportion of responders for placebo; 95% CI is calculated based on normal approximation.
SecondaryChange From Baseline in Platelet Counts on Scheduled Procedure Day

Last observation carried forward was used for participants with a missing platelet count on the scheduled procedure day. Platelet count was measured preprocedure and before any platelet transfusion.

Time frame:
Baseline (Visit 2) to Procedure Day 10 to Day 13 (Visit 4)
Reported as:
Mean · platelet count x 10^9 per liter
Change From Baseline in Platelet Counts on Scheduled Procedure Day
platelet count x 10^9 per liter60 mg Placebo (Lower Baseline Platelet Count)60 mg Avatrombopag (Lower Baseline Platelet Count)40 mg Placebo (Higher Baseline Platelet Count)40 mg Avatrombopag (Higher Baseline Platelet Count)
Change From Baseline in Platelet Counts on Scheduled Procedure Day3.0 ± 10.0131.3 ± 24.95.9 ± 14.8944.9 ± 32.96
Statistical analysis
  • 60 mg Placebo (Lower Baseline Platelet Count) vs 60 mg Avatrombopag (Lower Baseline Platelet Count) · Wilcoxon Rank Sum Test · p = <0.0001 · Difference in change of platelet count: 25.4 · 95% CI 19.5 to 32.0Difference in change from Baseline of platelet count for avatrombopag versus placebo within each Baseline platelet count cohort was based on Hodges-Lehmann estimation; 95% CI was the asymptotic (Moses) CI
  • 40 mg Placebo (Higher Baseline Platelet Count) vs 40 mg Avatrombopag (Higher Baseline Platelet Count) · Wilcoxon Rank Sum Test · p = <0.0001 · Difference in change of platelet count: 36.3 · 95% CI 25.5 to 45.5Difference in change from baseline of platelet count for avatrombopag vs. placebo within each baseline platelet count cohort is based on Hodges-Lehmann estimation; 95% confidence interval is the asymptotic (Moses) CI.
Other pre-specifiedPercentage of Participants With a World Health Organization (WHO) Bleeding Score Greater Than or Equal to 2 After Randomization and up to 7 Days After an Scheduled Procedure

The severity of bleeding events was assessed by the investigator (or appropriately delegated study site personnel) using the WHO bleeding scale. The WHO bleeding scale is a clinical investigator-assessed five-point scale with Grade 0 = No bleeding, Grade 1 = Petechial bleeding, Grade 2 = Mild blood loss (clinically significant), Grade 3 = Gross blood loss requires transfusion (severe), and Grade 4 = Debilitating blood loss, retinal or cerebral associated with fatality. Participants with missing information are considered as having a WHO bleeding score greater than or equal to 2 in the analysis.

Time frame:
Baseline (Visit 2) up to 7 days post scheduled procedure
Reported as:
Number · Percentage of participants
Percentage of Participants With a World Health Organization (WHO) Bleeding Score Greater Than or Equal to 2 After Randomization and up to 7 Days After an Scheduled Procedure
Percentage of participants60 mg Placebo (Lower Baseline Platelet Count)60 mg Avatrombopag (Lower Baseline Platelet Count)40 mg Placebo (Higher Baseline Platelet Count)40 mg Avatrombopag (Higher Baseline Platelet Count)
Percentage of Participants With a World Health Organization (WHO) Bleeding Score Greater Than or Equal to 2 After Randomization and up to 7 Days After an Scheduled Procedure0.01.46.11.7
Other pre-specifiedNumber of Participants Experiencing an Adverse Event

Safety assessments consisted of monitoring and recording all adverse events (AEs) and serious adverse events, including platelet transfusion-related complications; routine laboratory evaluation for hematology, serum chemistry, and urine values; periodic measurement of vital signs and electrocardiograms (ECGs); the performance of physical examinations; and Doppler sonography. AE severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death related to the AE. All AEs graded as 4 or 5 were considered to be serious. Treatment-emergent adverse events (TEAEs) were defined as an AE that started on or after the date of first dose of study drug, up to 30 days after the last dose of study drug. Treatment-related AEs were considered by the investigator to be possibly or probably related to study drug.

Time frame:
From date of first dose of study drug up to 30 days after the last dose of study drug, up to approximately 3 years and 2 months
Reported as:
Count of participants · Participants
Number of Participants Experiencing an Adverse Event
Participants60 mg Placebo (Lower Baseline Platelet Count)60 mg Avatrombopag (Lower Baseline Platelet Count)40 mg Placebo (Higher Baseline Platelet Count)40 mg Avatrombopag (Higher Baseline Platelet Count)
TEAEs22361528
Treatment-related TEAEs9624
Serious TEAEs1111
TEAEs leading to study drug dose adjustment0000
TEAEs leading to study drug withdrawal0000
TEAEs leading to study drug dose reduction0000
TEAEs leading to study drug dose interruption0000

Adverse events

Collected over From date of first dose of study drug up to 30 days after the last dose of study drug, up to approximately 3 years and 2 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
60 mg Placebo (Lower Baseline Platelet Count)0/43 (0%)1/43 (2.3%)22/43 (51.2%)
60 mg Avatrombopag (Lower Baseline Platelet Count)0/70 (0%)1/70 (1.4%)30/70 (42.9%)
40 mg Placebo (Higher Baseline Platelet Count)1/33 (3%)1/33 (3%)15/33 (45.5%)
40 mg Avatrombopag (Higher Baseline Platelet Count)0/57 (0%)1/57 (1.8%)14/57 (24.6%)
Most frequent serious events
Most frequent serious events
Event60 mg Placebo (Lower Baseline Platelet Count)60 mg Avatrombopag (Lower Baseline Platelet Count)40 mg Placebo (Higher Baseline Platelet Count)40 mg Avatrombopag (Higher Baseline Platelet Count)
Acute myocardial infarctionCardiac disorders0/430/701/330/57
Multiple organ dysfunction syndromeGeneral disorders0/430/701/330/57
Hepatic encephalopathyNervous system disorders1/430/700/330/57
Ileus paralyticGastrointestinal disorders0/430/700/331/57
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/430/700/331/57
HaematemesisGastrointestinal disorders0/431/700/330/57
Most frequent other events
Showing 10 of 11
Most frequent other events
Event60 mg Placebo (Lower Baseline Platelet Count)60 mg Avatrombopag (Lower Baseline Platelet Count)40 mg Placebo (Higher Baseline Platelet Count)40 mg Avatrombopag (Higher Baseline Platelet Count)
PyrexiaGeneral disorders2/4311/704/334/57
Abdominal pain upperGastrointestinal disorders5/432/703/331/57
NauseaGastrointestinal disorders5/436/702/333/57
HeadacheNervous system disorders4/432/701/332/57
Puncture site haemorrhageGeneral disorders0/430/703/330/57
Abdominal painGastrointestinal disorders3/432/701/332/57
DiarrhoeaGastrointestinal disorders3/433/700/332/57
FatigueGeneral disorders3/431/700/332/57
DizzinessNervous system disorders3/433/701/330/57
Transfusion reactionInjury, poisoning and procedural complications1/430/702/330/57

Baseline characteristics

Full Analysis Set (FAS) was defined as the group of all randomized participants.

Age, Continuous
Age, Continuous(years)60 mg Placebo (Lower Baseline Platelet Count)60 mg Avatrombopag (Lower Baseline Platelet Count)40 mg Placebo (Higher Baseline Platelet Count)40 mg Avatrombopag (Higher Baseline Platelet Count)Total
Mean57.3 ± 11.9858.6 ± 14.1859.2 ± 10.3157.9 ± 11.1158.2 ± 12.24
Sex: Female, Male
Sex: Female, Male(Participants)60 mg Placebo (Lower Baseline Platelet Count)60 mg Avatrombopag (Lower Baseline Platelet Count)40 mg Placebo (Higher Baseline Platelet Count)40 mg Avatrombopag (Higher Baseline Platelet Count)Total
Female1620162577
Male27501733127
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)60 mg Placebo (Lower Baseline Platelet Count)60 mg Avatrombopag (Lower Baseline Platelet Count)40 mg Placebo (Higher Baseline Platelet Count)40 mg Avatrombopag (Higher Baseline Platelet Count)Total
Hispanic or Latino121171545
Not Hispanic or Latino29562542152
Unknown or Not Reported23117
Race (NIH/OMB)
Race (NIH/OMB)(Participants)60 mg Placebo (Lower Baseline Platelet Count)60 mg Avatrombopag (Lower Baseline Platelet Count)40 mg Placebo (Higher Baseline Platelet Count)40 mg Avatrombopag (Higher Baseline Platelet Count)Total
American Indian or Alaska Native00000
Asian102581255
Native Hawaiian or Other Pacific Islander00000
Black or African American22026
White27402440131
More than one race430411
Unknown or Not Reported00101
08

Study locations

122 sites
  • Birmingham, Alabama, United States
  • Phoenix, Arizona, United States
  • Little Rock, Arkansas, United States
  • Coronado, California, United States
  • Loma Linda, California, United States
  • Denver, Colorado, United States
  • Miami, Florida, United States
  • Maywood, Illinois, United States
  • Indianapolis, Indiana, United States
  • Kansas City, Kansas, United States
  • New Orleans, Louisiana, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Kansas City, Missouri, United States
  • New York, New York, United States
  • Statesville, North Carolina, United States
  • Charleston, South Carolina, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Charlottesville, Virginia, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
  • Ciudad Autonoma Buenos Aires, Argentina
  • Cordoba, Argentina
  • Rosario, Argentina
  • Clayton, Victoria, Australia
  • Footscray, Victoria, Australia
  • Melbourne, Victoria, Australia
  • Parkville, Victoria, Australia
  • Edegem, Belgium
  • Gent, Belgium
  • Liege, Belgium
  • Aracaju, Brazil
  • Botucatu, Brazil
  • Porto Alegre, Brazil
  • Salvador, Brazil
  • Calgary, Canada
  • Edmonton, Canada
  • Hefei, Anhui, China
  • Beijing, Beijing, China
  • Shijiazhuang, Hebei, China
  • Nanjing, Jiangsu, China
  • Xi'an, Shaanxi, China
  • Xi'an, Shanxi, China
  • Chengdu, Sichuan, China
  • Hangzhou, Zheijiang, China
  • Brno, Czechia
  • Havirov, Czechia
  • Ostrava, Czechia
  • Praha 2, Czechia
  • Praha 4, Czechia
  • Usti nad Labem, Czechia
  • Nice Cedex 3, Alpes Maritimes, France
  • Clichy cedex, Hauts De Seine, France
  • Rennes cedex 09, Ille Et Vilaine, France
  • Lyon Cedex 04, Rhone, France
  • Villejuif, Val De Marne, France
  • Mannheim, Baden Wuerttemberg, Germany
  • Tuebingen, Baden Wuerttemberg, Germany
  • Frankfurt, Hessen, Germany
  • Hannover, Niedersachsen, Germany
  • Bonn, Nordrhein Westfalen, Germany
  • Leipzig, Sachsen, Germany
  • Kiel, Schleswig Holstein, Germany
  • Hamburg, Germany
  • Haifa, Israel
  • Holon, Israel
  • Jerusalem, Israel
  • Nahariya, Israel
  • Petach Tikva, Israel
  • Ramat-Gan, Israel
  • Rechovot, Israel
  • Tel Aviv, Israel
  • Baggiovara, Modena, Italy
  • Firenze, Italy
  • Milano, Italy
  • Pisa, Italy
  • Roma, Italy
  • Trento, Italy
  • Sapporo-shi, Hokkaido, Japan
  • Nishinomiya, Hyogo, Japan
  • Morioka, Iwate, Japan
  • Takamatsu, Kagawa, Japan
  • Yufu, Oita, Japan
  • Okayama-shi, Okayama, Japan
  • Osaka-Sayama-shi, Osaka, Japan
  • Osaka-shi, Osaka, Japan
  • Iruma, Saitama, Japan
  • Bunkyo-ku, Tokyo, Japan
  • Chiyoda, Tokyo, Japan
  • Musashino, Tokyo, Japan
  • Setagaya-ku, Tokyo, Japan
  • Shinagawa-ku, Tokyo, Japan
  • Chiba, Japan
  • Niigata, Japan
  • Okayama, Japan
  • Tokushima, Japan
  • Wakayama, Japan
  • Zapopan, Jalisco, Mexico

Showing the first 100 of 122 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Poordad F, Terrault NA, Alkhouri N, Tian W, Allen LF, Rabinovitz M. Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies. Int J Hepatol. 2020 Jan 25;2020:5421632. doi: 10.1155/2020/5421632. eCollection 2020. PubMed 32047671 ↗
  • Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. Gastroenterology. 2018 Sep;155(3):705-718. doi: 10.1053/j.gastro.2018.05.025. Epub 2018 May 17. PubMed 29778606 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Jan 2017, 38 months.

Results were first posted in Feb 2018, 1 year after primary completion.

Of 29 phase 3 interventional studies under Thrombocytopenia, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 45. This study's 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2013
First posted
Nov 5, 2013
StartActual
Nov 2013
Primary completionActual
Jan 30, 2017
CompletionActual
Feb 21, 2017
Results first posted
Feb 27, 2018
Last update
Feb 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01976104
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Nov 5, 2013
Start date
Nov 2013
Primary completion
Jan 30, 2017
Completion
Feb 21, 2017
Results posted
Feb 27, 2018
Last update
Feb 27, 2018

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avatrombopag

Start the discussion